Clinical trial

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

NCT03216902

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-07-25

PhasePHASE2

Study timeline

Study start (actual)2017-07-25Date precision: day

Registry last updated2020-10-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Open-angle Glaucoma, Ocular Hypertensionunresolved

Interventions

Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic SolutionDRUG

Topical ultra-low dose of DE-126 Ophthalmic SolutionDRUG

Topical low dose of DE-126 Ophthalmic SolutionDRUG

Topical medium dose of DE-126 Ophthalmic SolutionDRUG

Topical high dose of DE-126 Ophthalmic SolutionDRUG

0.005% Latanoprost Ophthalmic SolutionDRUG

Sponsors & collaborators

Santen Inc.lead sponsor

Mapped research locations

San AntonioTexas, United States1 AustinTexas, United States1 RochesterNew York, United States1 CharlotteNorth Carolina, United States1 Newport BeachCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03216902 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.